Delving into the Latest Updates on Fondazione IRCCS Istituto Neurologico Carlo Besta with Synapse

概览

关联

1

项与 Fondazione IRCCS Istituto Neurologico Carlo Besta 相关的药物

Dendritic Cells Vaccine(Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta)

靶点-

作用机制

免疫刺激剂

在研机构-

原研机构

Fondazione IRCCS Istituto Neurologico Carlo Besta

在研适应症-

非在研适应症-

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

72

项与 Fondazione IRCCS Istituto Neurologico Carlo Besta 相关的临床试验

NCT06584097 / RecruitingN/AIIT

COMparative Performance of General Purpose Models for Propofol and REmifentanil in Neurosurgical Patients Admitted to the Intensive Care Unit

To compare the performance of the Eleveld models for propofol and remifentanil on neurosurgery patients admitted to intensive care with their intraoperative performance.

开始日期2024-10-02

申办/合作机构

Fondazione IRCCS Istituto Neurologico Carlo Besta

[+1]

NCT06409845 / RecruitingN/AIIT

Effectiveness and Tolerability of Eptinezumab: a Prospective, Multicentric, Cohort Study

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

开始日期2024-03-26

申办/合作机构

University of Florence

[+7]

NCT06409832 / RecruitingN/AIIT

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

开始日期2024-03-26

申办/合作机构

University of Florence

[+8]

100 项与 Fondazione IRCCS Istituto Neurologico Carlo Besta 相关的临床结果

登录后查看更多信息

0 项与 Fondazione IRCCS Istituto Neurologico Carlo Besta 相关的专利（医药）

登录后查看更多信息

1,995

项与 Fondazione IRCCS Istituto Neurologico Carlo Besta 相关的文献（医药）

2024-12-31·Cogent Psychology

On the other side of ostracism: a systematic literature review of the cyberball overinclusion condition

作者: Telari, Alessia ; De Panfilis, Chiara ; Riva, Paolo ; Telesca, Alessandra ; Consonni, Monica

2024-12-01·Stem Cell Research

Generation of the CSSi020-A (14437) iPSC line from a patient carrying a copy number variation (CNV) in the 17p11.2 chromosome region

Article

作者: Zampino, Giuseppe ; Giovenale, Angela Maria Giada ; Ferrari, Daniela ; Bernardini, Laura ; Torres, Barbara ; Rosati, Jessica ; Turco, Elisa Maria ; Maria Giada Giovenale, Angela ; Luigi Vescovi, Angelo ; De Luca, Alessandro ; Mazzoni, Martina ; D'Arrigo, Stefano ; Maria Turco, Elisa ; Ferrone, Ilaria ; Vulcano, Edvige ; Pennuto, Maria ; Vescovi, Angelo Luigi ; D’Arrigo, Stefano ; Onesimo, Roberta

Smith-Magenis syndrome (SMS) is a complex neurodevelopmental disorder with a birth incidence of 1:25,000. SMS is caused by haploinsufficiency of the retinoic acid-induced retinoic acid1 (RAI1) gene, determined by an interstitial deletion of ∼ 3.7 Mb (17p11.2, including the RAI1 gene) in 90 % of cases and a mutation on the RAI1 gene in only 10 % of cases. We generated and characterized a human pluripotent stem cell line (hIPSCs) derived from primary fibroblasts of a 17-year-old woman carrying a 17p11.2 deletion including the RAI1 gene.

2024-12-01·Cognitive, Affective, & Behavioral Neuroscience

Deepening the decisional processes under value-based conditions in patients affected by Parkinson’s disease: A comparative study

Article

作者: Silveri, Maria Caterina ; Antonietti, Alessandro ; Iannello, Paola ; Elia, Antonio Emanuele ; Giovagnoli, Anna Rita ; Magni, Eugenio ; Colautti, Laura ; Pepe, Fulvio

AbstractPatients affected by Parkinson’s disease (PD) display a tendency toward making risky choices in value-based conditions. Possible causes may encompass the pathophysiologic characteristics of PD that affect neural structures pivotal for decision making (DM) and the dopaminergic medications that may bias choices. Nevertheless, excluding patients with concurrent impulse control disorders, results are few and mixed. Conversely, other factors, such as individual differences (e.g., emotional state, impulsivity, consideration for future consequences) and cognitive functioning, in particular executive functions (EFs), are involved, even though few studies investigated their possible role. The present study investigated (1) the differences in value-based DM between 33 patients with PD without impulse control disorders and 33 matched healthy controls, and (2) the relationships among decisional performances, EFs, and individual differences in a group of 42 patients with PD who regularly undertake dopaminergic medications. All participants underwent an individual assessment to investigate value-based DM, cognitive abilities, and individual differences associated with DM. Nonparametric analyses showed the presence of riskier decisions in patients compared with healthy controls, depending on the characteristics of the decisional situation. Moreover, parameters of the decisional tasks involving the number of risky choices were significantly related to the posology of dopaminergic medications, EFs, and individual differences. Findings were discussed, highlighting possible clinical implications.

100 项与 Fondazione IRCCS Istituto Neurologico Carlo Besta 相关的药物交易

登录后查看更多信息

100 项与 Fondazione IRCCS Istituto Neurologico Carlo Besta 相关的转化医学

登录后查看更多信息